Fast track to personalized TCR T cell therapies
- PMID: 35537408
- DOI: 10.1016/j.ccell.2022.04.013
Fast track to personalized TCR T cell therapies
Abstract
In this issue of Cancer Cell, Hanada et al. leverage single-cell multi-omics of lung cancer resident lymphocytes to identify phenotypic and transcriptomic signatures differentially expressed by neoantigen-reactive clonotypes. These findings could substantially expedite the selection of neoantigen-specific T cell receptors (TCRs) for individualized T cell therapies.
Trial registration: ClinicalTrials.gov NCT03412877 NCT04102436 NCT03970382 NCT05194735.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.G. is member of the scientific advisory boards (SABs) of Achilles Therapeutics plc, SingulaBIO, RootPath, Inc., and BioNTech SE, and consults for PACT Pharma, Inc. and Instil BIo. A.G. is co-inventor of patents licensed and with royalties related to this work: E−059-2013/0, E−085-2013/0, and E−149-2015/0. P.L. declares no competing interests.
Comment on
-
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.Cancer Cell. 2022 May 9;40(5):479-493.e6. doi: 10.1016/j.ccell.2022.03.012. Epub 2022 Apr 21. Cancer Cell. 2022. PMID: 35452604 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
